Frank Dellanna
Duesseldorf, NW 40210, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control.
Journal: Scientific reports
Published: April 04, 2025
Long-Term Excretion of Roxadustat in Urine.
Journal: Drug testing and analysis
Published: August 28, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials.
Journal: Advances in therapy
Published: July 11, 2023
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan.
Journal: Advances in therapy
Published: July 07, 2023
Safety and performance of the Clearum™ high flux hemodialyzer.
Journal: Artificial organs
Published: May 16, 2023
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Journal: Advances in therapy
Published: December 21, 2022
Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
Journal: Human vaccines & immunotherapeutics
Published: October 21, 2022
Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.
Journal: Critical reviews in oncology/hematology
Published: August 12, 2022
Detection of follistatin-based inhibitors of the TGF-β signaling pathways in serum/plasma by means of LC-HRMS/MS and Western blotting.
Journal: Drug testing and analysis
Published: May 22, 2020
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.
Journal: Kidney international reports
Published: May 23, 2019
Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study.
Journal: BMC nephrology
Published: September 10, 2018
First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.
Journal: PloS one
Published: August 02, 2018
Last Updated: 09/26/2026